Mpox vaccine procurement in Africa key to contain outbreak: Report
Mpox vaccine procurement for at-risk populations across Africa is crucial to contain the deadly outbreak and save lives, according to a report on Friday.
The report by GlobalData, a data and analytics company, noted that while Mpox vaccines played an important role in containing the 2022 mpox outbreak in high-income nations, “none are currently widely available in Africa”.
Bavarian Nordic’s MVA-BN vaccine (Jynneos/Imvanex) -- approved in the US, Europe, and Canada -- is the leading mpox vaccine worldwide.
In addition, KM Biologics’ LC16 vaccine is available in Japan and Emergent BioSolutions’ ACAM2000 is also under regulatory review for mpox in the US.
Fiona Chisholm, Associate Director of Infectious Diseases at GlobalData, called for a coordinated international response to put “press...









